Avastin licensed for ovarian, fallopian tube and peritoneal cancers

Bevacizumab (Avastin) is now indicated in combination with carboplatin and paclitaxel as a front-line treatment for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.

Bevacizumab is a recombinant humanised monoclonal antibody
Bevacizumab is a recombinant humanised monoclonal antibody
In addition to carboplatin and paclitaxel, bevacizumab should be administered by intravenous infusion at a dose of 15mg/kg every three weeks, for up to 6 cycles of treatment. Bevacizumab is then continued as a single agent until disease progression or for a maximum of 15 months or unacceptable toxicity, whichever occurs earlier.
    
Two multicentre, randomised phase III trials evaluated the safety and efficacy of the addition of bevacizumab to carboplatin and paclitaxel compared with the chemotherapy regimen alone in patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. The primary endpoint in both trials was progression-free survival (PFS).

The double-blind, placebo-controlled study GOG-0218 involved 1,873 previously untreated women, who received bevacizumab 15mg/kg every 3 weeks for up to 15 months. Patients who received bevacizumab throughout their chemotherapy treatment experienced 18.2 months of PFS, compared with 12 months for patients who received standard chemotherapy plus a placebo (HR=0.62 [95% CI, 0.52-0.75]; p<0.0001).

The two-arm, open-label ICON7 study involved 1,528 women with early stage and advanced disease and used a lower dose for a shorter duration of bevacizumab (7.5mg/kg every 3 weeks for up to 12 months). Median PFS was 16.9 months with standard therapy and 19.3 months with standard therapy plus bevacizumab (HR=0.86 [95% CI, 0.75-0.98]; p=0.001).

Bevacizumab is currently used for treating advanced breast cancer, colorectal cancer, non-small cell lung cancer and renal cancer.

View Avastin drug record

Further Information: Roche Products Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New antibiotic prescribing guidance issued for pneumonia

New antibiotic prescribing guidance issued for pneumonia

NICE has published antimicrobial prescribing guidelines...

MIMS summary of NICE COPD guidance updated

MIMS summary of NICE COPD guidance updated

Prescribers can now consult the quick-reference MIMS...

Soft-mist inhaler now available as reusable device

Soft-mist inhaler now available as reusable device

Respimat is now available as a reusable inhaler that...

NICE recommends 'innovative' treatment for type I diabetes

NICE recommends 'innovative' treatment for type I diabetes

Dapagliflozin (Forxiga) has been approved for routine...